Intersection of ferroptosis and nanomaterials brings benefits to breast cancer
Authors:
Open Access
- 22 July 2025
- journal article
- review article
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-43
Abstract
Breast cancer (BC) is the most frequently diagnosed malignancy among women worldwide, with a high incidence and mortality rate. Despite advances in treatment, approximately 10%–15% of patients with BC still face recurrence. Therefore, improving BC therapy remains a significant challenge. In this article, we provide a detailed overview, categorizing and elaborating the developments of current research progress on nanodrug delivery systems based on ferroptosis for BC treatment. By increasing the iron content in BC cells and inhibiting the defense system against ferroptosis, the accumulation of lipid peroxides is promoted, and ferroptosis is induced in BC cells. In addition to directly targeting tumor cells, nanodrug delivery systems can remodel the tumor microenvironment, inhibit BC primary growth, and prevent distant metastasis. These nanomaterials, after drug loading and modification, possess characteristics such as smart activation, controlled release, specific targeting, good biocompatibility, and long circulation time, thereby enhancing the efficacy of BC treatment. We also classify and discuss the mechanisms and advantages of different types of nanomaterials. Finally, we discuss how multifunctional nanosystems can sensitize ferroptosis when combined with radiotherapy, chemotherapy, immunotherapy, and phototherapy to achieve synergistic effects in BC treatment. This work reveals the potential of ferroptosis-based nanomaterials in overcoming BC, analyzes the limitations of the clinical application and proposes possible solutions, offering a promising direction for future treatment strategies. Graphical Abstract 1. Ferroptosis-based nanodrugs induce ferroptosis by increasing intracellular iron levels, disrupting redox homeostasis, and promoting LPO accumulation. 2. Nanodrugs not only target BC cells, but also target TME. 3. Ferroptosis-based nanodrugs can also synergize with chemotherapy, radiotherapy, immunotherapy, PDT, PTT, and other treatment modalities for enhanced BC management.Keywords
This publication has 333 references indexed in Scilit:
- A Mitochondria‐Targeted Ferroptosis Inducer Activated by Glutathione‐Responsive Imaging and Depletion for Triple Negative Breast Cancer TheranosticsAdvanced Healthcare Materials, 2023
- Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor EfficacyAdvanced Materials, 2023
- Metabolic Intervention Nanoparticles for Triple‐Negative Breast Cancer Therapy via Overcoming FSP1‐Mediated Ferroptosis ResistanceAdvanced Healthcare Materials, 2022
- Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of GlioblastomaAdvanced Materials, 2022
- An Energy‐Storing DNA‐Based Nanocomplex for Laser‐Free Photodynamic TherapyAdvanced Materials, 2022
- Photosynthetic Oxygenation‐Augmented Sonodynamic Nanotherapy of Hypoxic TumorsAdvanced Healthcare Materials, 2021
- pH‐Sensitive Molecular‐Switch‐Containing Polymer Nanoparticle for Breast Cancer Therapy with Ferritinophagy‐Cascade Ferroptosis and Tumor Immune ActivationAdvanced Healthcare Materials, 2021
- Acidity‐Activatable Dynamic Nanoparticles Boosting Ferroptotic Cell Death for Immunotherapy of CancerAdvanced Materials, 2021
- Engineered Cell‐Membrane‐Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer ImmunityAdvanced Materials, 2020
- Monodisperse and Uniform Mesoporous Silicate Nanosensitizers Achieve Low‐Dose X‐Ray‐Induced Deep‐Penetrating Photodynamic TherapyAdvanced Materials, 2019